| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3792 | Navarixin | 473727-83-2 | Navarixin (formerly known as MK-7123; SCH527123; PS291822) is a novel potent and specific allosteric antagonist of CXCR1 and CXCR2 with antitumor and anti-inflammatory activity and is able to sensitize cells to oxaliplatin in preclinical colon cancer models. |
|
V129565 | AT009 | AT009 is a humanized monoclonal antibody against CXCR4 that can be used in cancer research. | |
|
V2585 | ATI-2341 | 1337878-62-2 | ATI-2341 (ATI2341), a pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is a novel and selective allosteric agonist of CXCR4 with anti-inflammatory and anticancer activity. |
|
V3799 | AZD8797 | 911715-90-7 | AZD8797 (AZD-8797) is a novel, selective, orally bioavailable and allosteric non-competitive modulator of the human CX3CR1 receptor with potential anti-Inflammatory and immunomodulatory activity. |
|
V106153 | CXCL9(74-103) | CXCL9(74-103) is a derivative peptide of CXCL9, which has a high affinity for glycosaminoglycan (GAG) and can bind to GAG. | |
|
V51660 | CXCR2 antagonist 2 | 2647464-91-1 | CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immune research with IC50 of 95 nM. |
|
V3791 | CXCR2-IN-1 | 1873376-49-8 | CXCR2-IN-1 is a novel CNS (central nervous system) penetrant antagonist of CXCR2 with a pIC50 of 9.3. |
|
V83390 | CXCR3 antagonist 1 | 870998-13-3 | |
|
V79685 | CXCR4-IN-2 | CXCR4-IN-2 (compound A1) is a bifunctional fluorinated small molecule, a potent CXCR4 inhibitor (antagonist) with anti-cancer activity. | |
|
V3796 | Danirixin | 954126-98-8 | Danirixin (formerly known asGSK-1325756; GSK1325756) is a novel, potent small molecule CXCR2 antagonist being developed as a potential anti-inflammatory drug for COPD. |
|
V135035 | Eltrekibart | 2484883-56-7 | Eltrekibart is a monoclonal antibody against CXCL human IgG4κ. |
|
V137346 | HFB-100204 | HFB-100204 is a human monoclonal antibody (mAb) that targets CXCR5. | |
|
V112540 | Hypoglaucin A | 93528-39-3 | Hypoglaucin A is a CXCR3 antagonist with an IC50 value of 0.47 μM. |
|
V4031 | LIT-927 | 2172879-52-4 | LIT-927 (LIT927 ) is a novel potent, locally and orally bioactive neutraligand for the chemokine CXCL12 with anti-inflammatory and anticancer activity. |
|
V74886 | PS372424 hydrochloride | 1596362-29-6 | PS372424 HCl, a three-amino acid (AA) fragment of CXCL10, is a specific human CXCR3 agonist/activator with anti-inflammatory activity. |
|
V1490 | SB225002 | 182498-32-4 | SB225002 (SB 225002; SB-225002) is a novel, potent, and selective non-peptide antagonist of chemokine receptor CXCR2 with potential anti-inflammatory activity. |
|
V3795 | SCH 563705 | 473728-58-4 | SCH-563705 (SCH563705) is a novel potent and orally bioactive antagonist of CXCR2 and CXCR1 with anti-Inflammatory and immunomodulatory activity. |
|
V144672 | SCH-900875 | 907206-98-8 | SCH-900875 is an orally effective, blood-brain barrier-penetrating, and highly selective CXCR3 receptor inhibitor, which also exhibits high selectivity for CXCR1 and CXCR2 receptors. |
|
V86585 | SDF-1α (human) (TFA) | SDF-1α (human) TFA is a monocyte chemoattractant that binds to the CXCR4 receptor. | |
|
V145032 | SLW131 | 681511-84-2 | SLW131 is a CCR7 antagonist with good affinity and a Ki value of 9.85 nM. |